Table 3.

Inhibitory activity against Cell-to-Cell HIV transmission by NBD compounds.

A. Chronically infected cells H9-HIV-1IIIB and Molt-HIV-1ADA were used as donor cells and TZMb-l were used as acceptor cells.
Compound	IC50 (μM)a
	TZMb-l/H9-HIV-1IIIB	TZMb-l/Molt-HIV-1ADA
NBD-14107	0.56±0.03	1.7±0.1
48	0.41±0.07	1±0.1
39	0.079±0.003	0.44±0.002
55	0.097±0.006	0.3±0.02
BMS-626529	0.025±0.005	~0.4

B. PBMC cells acutely infected with lab-adapted and primary clinical isolates HIV-1 were used as donor cells and TZMb-l were used as acceptor cells.
Viral Strain	Subtype/coreceptor	IC50 (μM)a
		NBD-14107	48	39	55	BMS-626529
HIV-193RW018	A / R5	2.5±0.1	2.4±0.3	0.2±0.006	0.18±0.01	~0.1
HIV-193RW034	A / R5	0.89±0.07	0.87±0.01	0.29±0.02	0.19±0.01	~0.1
HIV-1LAIb	B / X4	0.73±0.03	0.31±0.01	0.21±0.05	0.26±0.05	~0.1
HIV-189.6b	B / R5X4	2.6±0.3	0.54±0.1	0.25±0.004	0.33±0.01	~0.1
HIV-1BaLb	B / R5	0.64±0.1	0.45±0.03	0.23±0.01	0.33±0.02	~0.1
HIV-192US073	B / R5	1.2±0.05	0.66±0.05	0.22±0.01	0.16±0.001	~0.1
HIV-192US657	B / R5	3.6±0.2	1.2±0.08	0.59±0.05	0.71±0.03	~0.1
HIV-193BR019	BF/ X4	1.9±0.16	0.25±0.04	0.31±0.01	0.2±0.006	~0.1
HIV-1CMU02	EA / X4	4.5±0.3	4.2±0.5	1.87±0.01	1.1±0.14	>6
HIV-1Ru132	G / R5	0.84±0.1	0.57±0.03	0.33±0.1	0.3±0.02	~0.1
HIV-1RU570	G / R5	1.3±0.1	0.28±0.006	0.37±0.004	0.32±0.01	~0.1
HIV-1BCF01	O / R5	0.96±0.06	0.31±0.03	0.28±0.06	0.22±0.01	>6
HIV-1BCF03	O / R5	2.2±0.06	0.71±0.05	1.6±0.08	0.18±0.01	>6
Mean ± SEM (μM): (n=13)		1.84±0.3	0.98±0.3	0.52±0.15	0.34±0.07	-
Toxicity in-infected PBMC : CC50 (μM)		>60	~61	~61	38.7±3.8	>10

^aThe reported IC₅₀ values represent the means ± standard deviation (SD), n=3.

^aThe reported IC₅₀ values represent the means ± standard deviation (n = 3).

^bLaboratory-adapted virus; all the rest are clinical isolate viruses